Rencontrez-nous à…

Toute l’actualité d’OTR3

  • A Retrospective Self-Controlled Study Evaluating the Prophylactic Effects of CACIPLIQ20 on Postsurgical Scars

    Media Publications

    Gilbert Zakine, MD, PhD; Anne Perruisseau-Carrier, MD, PhD; Corinne Becker, MD; Frédéric Sedel, MD, PhD; Luc Téot, MD; and Denis Barritault, PhD Abstract Background: CACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic that accelerates tissue [...]

  • Apr, 2023 – Publication

    News

    OTR3 is proud to share a recent publication in the “Aesthetic Surgery Journal Open Forum” from the Oxford University Press concerning “a retrospective self-controlled study evaluating the Prophylactic Effects of our Medical Device Cacipliq 20 on Postsurgical scars.” https://doi.org/10.1093/asjof/ojad031 Aesthetic Surgery Journal Open Forum (ASJOF) is an international award-winning, peer-reviewed, [...]

  • Regenerating matrix-based therapy for chronic wound healing

    DERMAPLIQ

    Dermapliq - Regenerating matrix-based therapy for chronic wound healing Suzanne L Groah, Alexander Libin, Miriam Spungen, Kim-Loan Nguyen, Earthaleen Woods, Marjan Nabili, Jessica Ramella-Roman, Denis Barritault The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan sulphate mimetic (CACIPLIQ20) improves chronic wound healing. [...]

  • Clerapliq – JAMA Ophtalmology

    CLERAPLIQ

    Clerapliq - Jama Ophtalmology clinical trial 2016 Oct 1;134(10):1169-1176. doi: 10.1001/jamaophthalmol.2016.3019. Ahmed M Bata , Katarzyna J Witkowska , Piotr A Wozniak , Klemens Fondi , Gerald Schmidinger , Niklas Pircher , Stephan Szegedi , Valentin Aranha Dos Santos , Anca Pantalon , René M Werkmeister, Gerhard Garhofer , [...]

  • Clerapliq – Topical Treatment with a New Matrix Therapy Agent

    CLERAPLIQ

    Clerapliq - Topical Treatment with a New Matrix Therapy Agent Abdelouahab Aifa, Julie Gueudry, Alexandre Portmann, Agn`es Delcampe, and Marc Muraine PURPOSE. Neurotrophic keratopathy is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, possibly leading to perforation. We aimed to assess the efficacy and tolerance [...]

  • Clerapliq – L’essentiel (FR)

    CLERAPLIQ

    Clerapliq -Prise en charge médicale des ulcères cornéens avec RGTA Cas clinique - L'Essentiel Bertrand Michaud - Docteur vétérinaire Les ulcères cornéens sont des affections fréquemment rencontrées en pratique vétérinaire quotidienne. Leur trai- tement passe par la mise en évidence de l’origine de la lésion. Ainsi, le traitement devra [...]

  • Mar 25, 2022 – Clinical

    News

    OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).

  • Feb 10, 2022 – Clinical

    News

    OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..